Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1CheckMate 451 (NI ; all population), 20191CheckMate 451 (N ; all population), 2019nivolumab alone vs. nivolumab plus ipilimumab 0.91 [0.69; 1.21]0.91 [0.69;1.21]nivolumab alone vs. nivolumab plus ipilimumab 0.91 [0.69; 1.21]nivolumab alone vs. placebo 0.84 [0.69; 1.02]0.84 [0.69;1.02]nivolumab alone vs. placebo 0.84 [0.69; 1.02]nivolumab plus ipilimumab vs. nivolumab alone 1.10 [0.83; 1.45]1.10 [0.83;1.45]nivolumab plus ipilimumab vs. nivolumab alone 1.10 [0.83; 1.45]nivolumab plus ipilimumab vs. placebo 0.92 [0.75; 1.12]0.92 [0.75;1.12]nivolumab plus ipilimumab vs. placebo 0.92 [0.75; 1.12]placebo vs. nivolumab alone 1.19 [0.98; 1.45]1.19 [0.98;1.45]placebo vs. nivolumab alone 1.19 [0.98; 1.45]placebo vs. nivolumab plus ipilimumab 1.09 [0.89; 1.33]1.09 [0.89;1.33]placebo vs. nivolumab plus ipilimumab 1.09 [0.89; 1.33]placebonivolumab plus ipilimumabnivolumab alonedirect evidencenetwork meta-analysis
T vs. C placebonivolumab plus ipilimumabnivolumab alone
placebo---1.09
0.89; 1.33		1.19
0.98; 1.45
nivolumab plus ipilimumab0.92
0.75; 1.12		---1.10
0.83; 1.45
nivolumab alone0.84
0.69; 1.02		0.91
0.69; 1.21		---

pathologies: 194 - treatments: 360,719,721,720 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons